T. Kawatani et al., Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies, EUR J HAEMA, 67(1), 2001, pp. 45-50
Hepatitis virus infection through virus reactivation has a high risk of mor
tality in patients with hematological malignancies receiving chemotherapy.
We examined the incidence of both hepatitis B virus (HBV) and hepatitis C v
irus (HCV) infection and severe liver dysfunction (alanine aminotransferase
> ten times the normal upper limit and total bilirubin >5 mg/dl) during ch
emotherapy in 268 patients with hematological malignancies. Eight patients
(3.0%) were infected with HBV and 22 patients (8.2%) were infected with HCV
. One patient (0.4%) was infected with both HBV and HCV. HBV- or HCV-infect
ed patients showed severe liver dysfunction at a significantly higher incid
ence than non-infected patients (11/31 (35.5%) vs. 0/237 (0%), p <0.0001).
Furthermore, the incidence of severe liver dysfunction in HBV-infected pati
ents was significantly higher than in HCV-infected patients (6/8 (75.0%) vs
. 4/22 (18.2%), p <0.01). Three of eight HBV-infected patients were initial
ly negative for hepatitis B surface antigen (HBsAg) by latex agglutination
and became positive for HBsAg during chemotherapy. Furthermore, all three p
atients developed severe liver dysfunction and two developed fatal fulminan
t hepatitis. From an examination of the original stock of serum samples bef
ore chemotherapy, two patients were found to be positive for HBV-DNA by pol
ymerase chain reaction (PCR). Although post-transfusion HBV infection was s
uspected in the one remaining patient, the cause of HBV infection could not
be clarified due to the impossibility of examination in blood donors. Sinc
e HBV-infected patients develop severe liver dysfunction at a higher incide
nce than either patients not infected with virus or HCV-infected patients b
efore chemotherapy for hematological malignancies, it is recommended that H
BV-DNA should be tested by PCR to detect HBV marker-negative carriers and l
iver function tests should be carefully monitored.